Prognostic Value of Combination of Pretreatment Red Cell Distribution Width and Neutrophil-to-Lymphocyte Ratio in Patients with Gastric Cancer
Table 2
Clinical pathological characteristics between different RDW + NLR groups.
Variables
RDW + NLR = 0, n (%)
RDW + NLR = 1, n (%)
RDW + NLR = 2, n (%)
Age
0.041
≤54
24 (23.3%)
20 (19.4%)
9 (8.7%)
>54
14 (13.6%)
17 (16.5%)
19 (18.4%)
Gender
0.565
Female
13 (12.6%)
16 (15.5%)
13 (12.6%)
Male
25 (24.3%)
21 (20.4%)
15 (14.6%)
Tumor location
0.014
Pyloric antrum
22 (21.4%)
21 (20.4%)
7 (6.8%)
Nonpyloric antrum
16 (15.5%)
16 (15.5%)
21 (20.4%)
HER-2
0.867
Positive
11 (10.7%)
11 (10.7%)
6 (5.8%)
Negative
20 (19.4%)
15 (14.6%)
10 (9.7%)
Unknown
7 (6.8%)
11 (10.7%)
12 (11.7%)
TNM stage
0.007
I-II
11 (10.7%)
8 (7.8%)
1 (1.0%)
III
13 (12.6%)
8 (7.8%)
4 (3.9%)
IV
14 (13.6%)
21 (20.4%)
23 (22.3%)
Metastasis
0.001
Yes
14 (13.6%)
21 (20.4%)
23 (22.3%)
No
24 (23.3%)
16 (15.5%)
5 (4.9%)
RDW (%)
<0.001
≤13.4%
38 (36.9%)
15 (14.6%)
0 (0.0%)
>13.4%
0 (0.0%)
22 (21.4%)
28 (27.2%)
WBC (g/L)
0.001
≤5.69
22 (21.4%)
21 (20.4%)
9 (8.7%)
>5.69
16 (15.5%)
16 (15.5%)
19 (18.4%)
MO (g/L)
0.830
≤0.42
21 (20.4%)
23 (22.3%)
9 (8.7%)
>0.42
17 (16.5%)
14 (13.6%)
19 (18.4%)
NLR
<0.001
≤2.755
38 (36.9%)
22 (21.4%)
0 (0.0%)
>2.755
0 (0.0%)
15 (14.6%)
28 (27.2%)
CA125 (U/mL)
0.022
≤26.6
23 (22.3%)
22 (22.3%)
11 (10.7%)
>26.6
15 (14.6%)
15 (14.6%)
17 (16.5%)
CA199 (U/mL)
0.042
≤11.9
23 (22.3%)
19 (18.4%)
14 (13.6%)
>11.9
15 (14.6%)
18 (17.5%)
14 (13.6%)
CEA (μg/L)
0.190
≤2.4
21 (20.4%)
22 (21.4%)
11 (10.7%)
>2.4
17 (16.5%)
15 (14.6%)
17 (16.5%)
RDW + NLR: combination of red blood cell distribution width and neutrophil-to-lymphocyte ratio; RDW: red cell distribution width; MO: monocyte; NLR: neutrophil-to-lymphocyte ratio. less than 0.05 is statistically significant.
